AstraZeneca Acquires KuDOS Pharmaceuticals For $210 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
The purchase provides AstraZeneca’s oncology division with DNA repair inhibitors in clinical, preclinical development.